Watch PHIO. Know when insiders buy.
One email the day a filing lands. Free.
Work order
41
WATCH · insiders 56, shorts 25
Insiders, 90 days
+$17K
net buying · 1 buy, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $12.5MP/E —DIV YIELD —FCF YIELD -97.31%REV TTM —NET INCOME −$12.9MNET CASH $13M52W 0.86 – 2.48SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4.3M | −$4.1M | — | -0.36 | −$4M | $0 | −$4M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$4.2M | −$4M | — | -0.34 | −$4M | $0 | −$4M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.5M | −$2.4M | — | -0.15 | −$2.1M | $0 | −$2.1M | Mar 5 |
| Q3 2025 · Sep 30 | — | — | — | −$2.5M | −$2.4M | — | -0.44 | −$2.1M | $7K | −$2.1M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$2.3M | −$2.2M | — | -0.45 | −$2.5M | $3K | −$2.5M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$1.9M | −$1.8M | — | -0.41 | −$1.3M | $2K | −$1.3M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.7M | −$1.6M | — | -0.85 | −$1.4M | $1K | −$1.4M | Mar 5 |
| Q3 2024 · Sep 30 | — | — | — | −$1.6M | −$1.5M | — | -1.54 | −$2M | $0 | −$2M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$1.9M | −$1.8M | — | -3.62 | −$1.8M | $0 | −$1.8M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$2.2M | −$2.2M | — | -0.47 | −$2M | $0 | −$2M | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.9M | −$1.9M | — | -1.48 | −$2.4M | $0 | −$2.4M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$2.8M | −$2.8M | — | -10.25 | −$2.9M | $0 | −$2.9M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$9.2M | −$8.7M | — | -1.45 | −$8M | $12K | −$8M | — | — |
| FY2024 · to Dec 31 | — | — | −$7.4M | −$7.2M | — | -9.08 | −$7.1M | $1K | −$7.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$10.8M | −$10.8M | — | -46.76 | −$10.7M | $5K | −$10.8M | — | — |
| FY2022 · to Dec 31 | — | — | −$11.5M | −$11.5M | — | -10.10 | −$12.1M | $121K | −$12.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$13.5M | −$13.3M | — | -12.43 | −$11.9M | $51K | −$11.9M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$8.8M | −$8.8M | — | -1.92 | −$8.8M | $19K | −$8.8M | — | — |
Every number comes from Phio Pharmaceuticals Corp.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.